An abstract submission has been accepted as a sub-study within RenovoRx’s Phase III TIGeR-PaC clinical trial. This abstract delves into the TAMP™ therapy platform's ability to enhance local drug potency while decreasing systemic exposure and the typical side effects associated with chemotherapy. This development is a significant component of RenovoRx's ongoing research, with potential implications for increasing treatment efficacy and reducing adverse effects for patients.